Phase |/||

Therapeutic Approach

Restoring or Replacing Dystrophin

Gene therapy for Duchenne is centered on the goal of successfully introducing a smaller, but efficient version of dystrophin into the muscle cell. RGX-202 is an investigational gene therapy product, utilizing a novel adeno-associated virus (AAV8) to transport a shortened version of the dystrophin gene (micro-dystrophin) that may provide benefit in place of the missing full-length dystrophin protein.


AFFINITY DUCHENNE a Phase 1/2 study is not yet recruiting. The FDA approved the IND for RGX-202 and it is anticipated to begin enrollment in the first half of 2022.


This program is sponsored by REGENXBIO.


JUNE 2021

REGENXBIO at the PPMD 2021 Virtual Annual Conference

Pre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library

Join Our Mailing List